UNSPSC 51241133: Dorzolamide hydrochloride

This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZO5366EW7. European Medicines Agency schedules Dorzolamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01820MIG. Dorzolamide hydrochloride generally arises in the molecular formula C10H16N2O4S3.CLH. The term 'dorzolamide hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule dorzolamide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, DORZOLAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dorzolamide hydrochloride bears US NLM identifiers UMLS ID C0771293 and NCI Concept Code C29003. SMILES: CCN[C@H]1C[C@@H](S(=O)(=O)C2C1CC(S2)S(=O)(=O)N)C.CL.

UNSPSC 51241133 Dorzolamide hydrochloride is a Commodity code covering a specific ophthalmic medication used to treat elevated intraocular pressure in glaucoma and ocular hypertension. State and local governments procure this pharmaceutical through health departments, corrections departments, veterans' affairs agencies, and public health clinics that operate direct patient-care or inmate medical programs. The medication is typically solicited as part of broader pharmaceutical formularies or in targeted RFPs for ophthalmology supplies and medications. Procurement offices generally require compliance with state pharmaceutical pricing agreements, federal rebate programs, and generic/brand equivalency rules that vary by issuing agency.

The source provided contains no recent state or local contract opportunities tagged to this code and supplies no geographic, issuing-body, or representative-opportunity data. Without posted RFPs, RFQs, IBFs, or ITBs naming this UNSPSC, activity under the code cannot be characterized by jurisdiction, state, or contracting pattern.